-
FDA Approves Bravnetsa (lutetium Lu 177 dotatate) as a Therapeutic Equivalent to Lutathera for the Treatment of Somatostatin Receptor-Positive Gastroenteropancreatic Neuroendocrine Tumors in Adults
NASDAQ: $LNTH BEDFORD, Mass., Sept. 22, 2026 (GLOBE NEWSWIRE) — Lantheus Holdings, Inc. (“Lantheus” or the “Company”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver… Source: Read More
-
A New Milestone in Alzheimer’s Diagnostics: FDA Approves Tauvid (Tauklartify)
NASDAQ: $LNTH Understanding the Breakthrough The landscape of Alzheimer’s disease diagnosis has taken a significant step forward. The FDA has officially approved Tauklartify (florquinitau F 18), a groundbreaking diagnostic agent designed to assist healthcare professionals in evaluating patients with cognitive impairment. How It Works Tauklartify is an F 18-labeled tau positron emission tomography (PET) imaging…